AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Imfinzi has been accepted and granted priority review in the U.S. for the treatment of patients with muscle-invasive bladder cancer.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca sBLA for Imfinzi granted Priority Review in MIBC
- AstraZeneca announces FDA approval for Imfinzi
- AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC
- AstraZeneca appoints Iskra Reic as Executive Vice President, International
- AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List